Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist
Panda, S
This association was consistent among patients ages 50 and older, Black and Asian patients, those prescribed GLP-1 receptor analogs and those with baseline HbA1c 8%, BMI 30kg/m2 and diabetes duration of three or more years
The RUO reagent is not a substitute for the drug under investigation and does not replace medical consultation
US$ 21.92
US$ 29.96
US$ 24.30
US$ 24.05
